Huntington’s Disease Treatment Market Report 2026

Huntington’s Disease Treatment Market Overview

• Huntington’s Disease Treatment market size has reached to $0.82 billion in 2025 • Expected to grow to $1.48 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: The Increase In Gene Therapies Is Fueling The Growth Of The Market Due To Their Ability To Target Genetic Causes And Slow Disease Progression • Market Trend: Advancements In Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Therapies For Huntington's Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Huntington’s Disease Treatment Market?

Huntington’s disease treatment involves medical therapies designed to manage the symptoms of this progressive neurological disorder. The primary goal is to slow disease progression, alleviate symptoms, and enhance the patient’s quality of life. The main types of Huntington’s disease treatment are symptomatic treatment and disease-modifying therapies. Symptomatic treatment focuses on alleviating Huntington’s disease symptoms and improving quality of life without addressing the underlying cause, and is increasingly in demand as patients seek better management of daily challenges. These treatments can be administered through various methods, including oral, intravenous, subcutaneous, and topical routes for various therapeutic applications, including genetic, neurological, and psychiatric disorders. The treatments are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end users, including hospitals, clinics, home care settings, and research institutions.

What Is The Huntington’s Disease Treatment Market Growth Forecast?

The huntington’s disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.48 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to advancements in gene therapy technologies, rising investment in rare disease research, increasing orphan drug designations, growing precision medicine adoption, expanding pipeline of disease-modifying therapies. Major trends in the forecast period include growing focus on disease-modifying therapies, increasing adoption of gene and RNA-based treatments, expansion of combination therapy approaches, rising emphasis on symptom-specific drug development, increasing clinical trial activity for rare neurological disorders.

Global Huntington’s Disease Treatment Market Segmentation

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies 2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical 3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers Subsegments: 1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers 2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

What Is The Driver Of The Huntington’s Disease Treatment Market?

The increase in gene therapies is expected to propel the growth of the Huntington’s disease treatment market going forward. Gene therapies are treatments that modify or replace faulty genes to cure or prevent diseases at the genetic level. Gene therapies are growing as precision medicine advances, enabling direct targeting of genetic causes and achieving better outcomes than traditional treatments. Gene therapies treat Huntington’s disease by silencing the defective HTT gene that generates harmful proteins, preventing nerve cell damage. This strategy helps slow disease progression, protect brain function, and offers potential for long-term control. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of Q1 2023, there were 247 gene therapies in phase II, but this number rose by 5% to reach 260 by the end of Q2. Therefore, the increase in gene therapies is driving the growth of the Huntington’s disease treatment industry.

Key Players In The Global Huntington’s Disease Treatment Market

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Global Huntington’s Disease Treatment Market Trends and Insights

Major companies operating in the Huntington’s disease treatment market are focused on developing advanced therapies such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules to potentially improve patient quality of life while slowing disease progression. Selective VMAT2 inhibitor capsules are medications that block the vesicular monoamine transporter 2, a protein involved in packaging neurotransmitters for brain release. These drugs help reduce neurotransmitter release, aiding in the management of involuntary movements and related symptoms. For instance, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for the treatment of chorea associated with Huntington's disease (HD) in adults. These capsules are a once-daily oral VMAT2 inhibitor, working by reducing excessive dopamine signaling in the brain to help control involuntary movements. The medication is available in multiple capsule strengths and can be taken with or without food, offering a convenient dosing option for patients.

What Are Latest Mergers And Acquisitions In The Huntington’s Disease Treatment Market?

In December 2024, PTC Therapeutics Inc., a US-based pharmaceutical company that is actively developing a treatment for Huntington’s disease, partnered with Novartis AG to provide a Huntington’s disease treatment. This partnership aims to accelerate the development and global commercialization of PTC518, a potential first-in-class oral, disease-modifying therapy for Huntington’s disease. Novartis AG is a Switzerland-based manufacturer of drugs for Huntington’s disease.

Regional Insights

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the huntington’s disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Huntington’s Disease Treatment Market?

The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Huntington’s Disease Treatment Market Report 2026?

The huntington’s disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the huntington’s disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.